Skinny Labels, Big Savings Act

The "Skinny Labels, Big Savings Act" (S 5573) creates a legal safe harbor to prevent patent infringement claims against generic and biosimilar drug manufacturers for marketing activities that avoid patented conditions of use. It protects actions like submitting applications for generic drugs (under FDA’s 505(j) pathway) or biosimilars (under 351(k)), promoting approved labeling, and describing drugs as generics or biosimilars - provided marketing never references the specific patented condition. This directly affects drug manufacturers seeking to market affordable alternatives and patent holders of method-of-use patents. The bill aims to reduce legal barriers to competition by clarifying that "skinny label" marketing (avoiding patented uses) does not infringe patents.